With increased use of immune checkpoint inhibitors (ICIs), a wide spectrum of rare immune-related adverse events (irAEs) are emerging.

Clinician awareness of rare irAEs is required for timely investigation and management. Delayed recognition can lead to high morbidity, mortality and poor overall outcomes for these patients.

Further understanding of the pathophysiology of these conditions will improve selection of appropriate biomarkers to help inform targeted approaches to management.